Orexo has a strong history of developing new products approved in markets all over the world. In order to ensure a continued inflow of new improved drugs, the development work at the R&D department in Uppsala, Sweden, has intensified. Filling an unmet need among healthcare professionals and patients is the key in the work of developing new innovative products for treatment of opioid addiction in all phases.

To follow all development phases for the products/projects, please use the scroll function in the bottom of this image.

Commercial products

Exploratory

Preclinical

1

2

3

Registration

US

EU

RoW1

Zubsolv®

— Opioid Dependence

Abstral®

— Breakthrough Cancer Pain

Partners:

Kyowa Kirin,

Sentynl Therapeutics

Edluar®

— Insomnia

Partners:

Mylan

Development projects

Exploratory

Preclinical

1

2

3

Registration

US

EU

RoW1

OX124

Naloxone

— Opioid overdose

OX125

Nalmefene

— Opioid overdose

OX338

Ketorolac

— Acute moderate to severe pain

OX382

Buprenorphine

— Opioid Dependence

OX-MPI

BI1029539

— Microvascular disease

Partners:

Gesynta Pharma

To read about each development project please go to the main menu Pipeline and its sub-menu.